Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical colorectal cancer Pub Date : 2024-02-16 DOI:10.1016/j.clcc.2024.02.001

Laura Roazzi , Giorgio Patelli , Katia Bruna Bencardino , Alessio Amatu , Erica Bonazzina , Federica Tosi , Brunella Amoruso , Anna Bombelli , Sara Mariano , Stefano Stabile , Camillo Porta , Salvatore Siena , Andrea Sartore-Bianchi

{"title":"Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer","authors":"Laura Roazzi , Giorgio Patelli , Katia Bruna Bencardino , Alessio Amatu , Erica Bonazzina , Federica Tosi , Brunella Amoruso , Anna Bombelli , Sara Mariano , Stefano Stabile , Camillo Porta , Salvatore Siena , Andrea Sartore-Bianchi","doi":"10.1016/j.clcc.2024.02.001","DOIUrl":null,"url":null,"abstract":"<div><div><span><span>Liquid biopsy<span> using circulating tumor DNA<span> (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of </span></span></span>metastatic colorectal cancer<span><span> (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and </span>metastases, and have mainly focused on the genotyping of </span></span><em>RAS</em> and <em>BRAF</em><span>, that is propaedeutic for anti-EGFR treatment selection. However, ctDNA soon broadened its scope towards the assessment of early tumor response, as well as the identification of drug resistance biomarkers to drive potential molecular actionability. In this review article, we provide an overview of the current state-of-the-art of this methodology and its applications, focusing on ongoing clinical trials that employ ctDNA to prospectively guide treatment in patients with mCRC.</span></div></div>","PeriodicalId":10373,"journal":{"name":"Clinical colorectal cancer","volume":"23 4","pages":"Pages 295-308"},"PeriodicalIF":3.3000,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical colorectal cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002824000069","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and metastases, and have mainly focused on the genotyping of RAS and BRAF, that is propaedeutic for anti-EGFR treatment selection. However, ctDNA soon broadened its scope towards the assessment of early tumor response, as well as the identification of drug resistance biomarkers to drive potential molecular actionability. In this review article, we provide an overview of the current state-of-the-art of this methodology and its applications, focusing on ongoing clinical trials that employ ctDNA to prospectively guide treatment in patients with mCRC.

查看原文本刊更多论文

循环肿瘤 DNA 治疗转移性结直肠癌的现行临床试验和未来研究方案

利用循环肿瘤 DNA（ctDNA）进行液体活检已成为一种微创、及时的方法，可为癌症患者提供分子诊断并监测肿瘤演变。由于转移性结直肠癌（mCRC）的分子结构在空间和时间上具有很大的异质性和动态性，ctDNA 作为该疾病的生物标记物具有显著优势。大量研究表明，ctDNA 能广泛再现原发肿瘤和转移灶的分子特征，并且主要集中在 RAS 和 BRAF 的基因分型上，这对抗肿瘤表皮生长因子受体（anti-EGFR）治疗的选择具有重要意义。然而，ctDNA 很快将其应用范围扩大到早期肿瘤反应评估以及耐药性生物标志物的鉴定，以推动潜在的分子可操作性。在这篇综述文章中，我们概述了这一方法的最新进展及其应用，重点介绍了正在进行的临床试验，这些试验采用ctDNA对mCRC患者的治疗进行前瞻性指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical colorectal cancer 医学-肿瘤学

CiteScore

5.50

自引率

2.90%

发文量

审稿时长

27 days

期刊介绍： Clinical Colorectal Cancer is a peer-reviewed, quarterly journal that publishes original articles describing various aspects of clinical and translational research of gastrointestinal cancers. Clinical Colorectal Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of colorectal, pancreatic, liver, and other gastrointestinal cancers. The main emphasis is on recent scientific developments in all areas related to gastrointestinal cancers. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.